Study identifier:13-601
ClinicalTrials.gov identifier:NCT01994382
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)
Follicular Lymphoma (FL/Indolent NHL)
Phase 1/2
No
Cerdulatinib
All
260
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2024 by Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Portola Pharmaceuticals
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Phase 1 Cerdulatinib During Phase 1, participants will receive oral cerdulatinib on Day 1 and then starting on Day 4 at doses of 15 mg up to 100 mg QD or oral cerdulatinib at doses of 15 mg up to 45 mg BID in 28-day cycles (except Cohort 1 will have a 21-day cycle starting on Day 1) for up to 10 cycles. | Drug: Cerdulatinib Oral capsule Other Name: PRT062070 Other Name: ALXN2075 |
| Experimental: Phase 2a Cerdulatinib During Phase 2a, participants in cohorts based on cancer type will receive oral cerdulatinib at starting doses of 35, 30, or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib can be reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval. | Drug: Cerdulatinib Oral capsule Other Name: PRT062070 Other Name: ALXN2075 |
| Experimental: Phase 2a Cerdulatinib plus Rituximab During Phase 2a, participants in this cohort will receive oral cerdulatinib at their applicable dose and an IV injection of rituximab 375 mg/m^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10. | Drug: Cerdulatinib Oral capsule Other Name: PRT062070 Other Name: ALXN2075 Biological/Vaccine: Rituximab IV infusion Other Name: Rituxan® Other Name: Truxima® Other Name: Rixathon® Other Name: Ruxience® Other Name: MabThera® |